Table 2 Prepatent (T1%) periods and statistical significance of protective efficacy.
Challenge | Comparison | Poly (I:C) | Montanide ISA720 | ||||
|---|---|---|---|---|---|---|---|
NLP-CSPCT vs. Adj | NLP-CSPR vs. Adj | NLP-CSPCT vs. NLP-CSPR | NLP-CSPCT vs. Adj | NLP-CSPR vs. Adj | NLP-CSPCT vs. NLP-CSPR | ||
Pb-PvCSP210 | Median T1% | 5.15 vs. 4.6 | 4.85 vs. 4.6 | 5.15 vs. 4.85 | 5.6 vs. 4.8 | 5.3 vs. 4.8 | 5.6 vs. 5.3 |
p values | p = 0.0008 | p = 0.0136 | n.s. p = 0.1026 | p = 0.0005 | p = 0.0068 | p = 0.0192 | |
Pb-PvCSP247 | Median T1% | 4.7 vs. 4.4 | 4.5 vs. 4.4 | 4.7 vs. 4.5 | 5.5 vs. 4.5 | 5.35 vs. 4.5 | 5.5 vs. 5.35 |
p values | p = 0.0049 | n.s. p = 3797 | p = 0.0136 | p = 0.0005 | p = 0.0005 | n.s. p = 0.2798 | |
Pb-PvCSP-like G10 | Median T1% | 5.6 vs. 5.05 | 5.7 vs. 5.05 | 5.6 vs. 5.7 | 5.75 vs. 5 | 5.85 vs. 5 | 5.75 vs. 5.85 |
p values | p = 0.0005 | p = 0.0012 | n.s. p = 0.9949 | p = 0.0007 | p = 0.0007 | n.s. p = 0.9910 | |
